サービス概要
アフコシル化抗体の生産のため、CHOK1-Fut8KO発現プラットフォームを新たに立ち上げました。当社のハイスループット・リコンビナント抗体発現プラットフォームと細胞培養技術との組み合わせ、研究および産業上のニーズに合わせてアフコシル化抗体を迅速に生産することができます。アフコシル化は、antibody-dependent cell-mediated cytotoxicity (ADCC)を著しく高めることが示されており、有効性を高めることにより標的療法の可能性を広げます。
アフコシル化抗体の生産のため、CHOK1-Fut8KO発現プラットフォームを新たに立ち上げました。当社のハイスループット・リコンビナント抗体発現プラットフォームと細胞培養技術との組み合わせ、研究および産業上のニーズに合わせてアフコシル化抗体を迅速に生産することができます。アフコシル化は、antibody-dependent cell-mediated cytotoxicity (ADCC)を著しく高めることが示されており、有効性を高めることにより標的療法の可能性を広げます。
ノックアウトされたFut8細胞株は、アフコシル化抗体の生産に適用されています。 Fut8は、α-1,6フコシルグリコシド結合の形成を触媒する酵素であり、したがって、アスパラギン酸に結合したN-アセチルグルコサミン部位へのフコースの付加を行います。
フコースフリー宿主細胞CHOK1BN-Fut8KOは、抗体の特性評価と機能検証を行った後、工業生産に使用することができます。一般的なCHOK1BN細胞株と比較して、CHOK1BN-Fut8KOによって産生された抗体は、アフコシル化が達成されるだけでなく、発現量と品質の面でも一貫性が保たれます。
| No. | Host cell | INN |
|---|---|---|
| 001 | CHOK1BN | Rituximab |
| 002 | CHOK1BN-Fut8KO |
001
002
The reduced mass matched the theoretical molecular weight of 001, the main N-glycosylation type on the heavy chain was G0, G1, and N-glycosylation type contain fucose.
The reduced mass matched the theoretical molecular weight of 002, the main N-glycosylation type on the heavy chain was G0, G1, and no N-glycosylation type contain fucose was found.
The results showed both antibodies demonstrated target cell killing activity, indicating their strong potential for immune-mediated cytotoxicity.
MW: 52/48/23kDa (123kDa)
This case highlights the production of a bispecific antibody using CHOK1BN-Fut8KO cells. After one-step Protein A purification, SDS-PAGE and analytical SEC-HPLC revealed the presence of high molecular weight impurities. A second round of purification was performed to improve purity. Reduced MS analysis confirmed that the antibody was afucosylated, with no N-glycosylation at the Fc region.
1st purification
2nd purification
The reduced mass matched the theoretical molecular weight of the light chain, and there is no N-glycosylation site.
The reduced mass matched the theoretical molecular weight of the heavy chain, and no N-glycosylation type contain fucose was found.
Afucosylated antibody expression involves producing antibodies without fucose residues in their Fc region. This modification enhances antibody-dependent cell-mediated cytotoxicity (ADCC), improving therapeutic efficacy.
Clients need to provide the antibody sequence or the hybridoma cell line producing the antibody. If the sequence is unavailable, Biointron offers sequencing services to obtain it.
Biointron utilizes a CHOK1BN-Fut8KO cell line, which lacks the Fut8 enzyme responsible for adding fucose to antibodies, ensuring the production of afucosylated antibodies.
The production process typically takes 2–4 weeks, depending on the project's complexity and specific requirements.
Biointron employs rigorous quality control protocols, including glycosylation profiling, purity verification, and functional assays, to ensure the antibodies meet the highest standards.
Yes, Biointron can produce afucosylated antibodies in various formats, including IgG, scFv, Fab, and bispecific antibodies, tailored to meet specific research or therapeutic needs.
Clients receive purified afucosylated antibody samples, along with detailed reports on production processes, quality control results, and any relevant assay data.
Biointron provides detailed instructions for sample preparation and shipping to ensure the integrity of your materials during transit.
To start, contact Biointron through the website’s inquiry form or email. A consultation will be arranged to discuss project requirements and provide a tailored proposal.
At Biointron, we are deeply committed to delivering top-quality products that surpass customer expectations. With every product we offer, we promise to provide unmatched quality, reliability, and satisfaction to our valued customers. Your trust in our brand fuels our passion for continuous improvement, ensuring that we consistently deliver nothing but the best.
ScientistとScience Exchangeとのご利用可能です。
